Lazard Asset Management’s BeOne Medicines Ltd ONC Stock Holding History

Lazard Asset Management’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7M	Buy	62,917 +14,696	+30%	+$4.76M	0.03%	332
2025 Q4	$14.7M	Buy	48,221 +6,841	+17%	+$2.24M	0.02%	366
2025 Q3	$14.1M	Buy	41,380 +17,688	+75%	+$5.37M	0.02%	365
2025 Q2	$5.74M	Buy	23,692 +11,197	+90%	+$2.75M	0.01%	693
2025 Q1	$3.4M	Buy	+12,495	New	+$2.92M	0.01%	806
2021 Q3	–	Sell	-3,055	Closed	-$1.05M	–	2316
2021 Q2	$1.05M	Buy	+3,055	New	+$1.01M	﹤0.01%	943
2021 Q1	–	Sell	-689	Closed	-$178K	–	2058
2020 Q4	$178K	Hold	689	–	–	﹤0.01%	1113
2020 Q3	$197K	Buy	+689	New	+$162K	﹤0.01%	967
2018 Q1	–	Sell	-1,580	Closed	-$154K	–	1134
2017 Q4	$154K	Buy	+1,580	New	+$145K	﹤0.01%	894

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Lazard Asset Management's ONC Position: Q1 2026 in Review

Lazard Asset Management increased its BeOne Medicines Ltd (ONC) stake by 30% in Q1 2026, buying an estimated $4.76M and bringing the position to 62,917 shares worth $18.7M. The position accounts for 0.03% of the portfolio, ranked #332.

Lazard Asset Management first reported a position in ONC in Q4 2017 and has held it in 9 quarters since. 281 funds tracked by Wall St. Rank hold ONC as of Q1 2026.

Lazard Asset Management held 62,917 shares of BeOne Medicines Ltd worth $18.7M as of Q1 2026.
Lazard Asset Management bought 14,696 BeOne Medicines Ltd shares in Q1 2026, an estimated $4.76M.
BeOne Medicines Ltd made up 0.03% of Lazard Asset Management's portfolio in Q1 2026, its #332 holding.
Lazard Asset Management first reported a position in BeOne Medicines Ltd in Q4 2017 and has held it in 9 quarters since.
281 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q1 2026.

Based on Lazard Asset Management's 13F filing for Q1 2026, filed 15 May 2026.